Rheumatoid arthritis is a systemic autoimmune disease whose most clinically prominent manifestation is persistent, symmetric inflammation of the synovial joints of the hands, wrists, feet, and larger joints, but whose disease process extends far beyond the joints to produce systemic inflammation with consequences for the cardiovascular system, lungs, bones, and neurological function that contribute substantially to the morbidity and premature mortality associated with the condition. Affecting approximately one percent of the global adult population with a two to three fold predominance in women, rheumatoid arthritis is the most common inflammatory arthritis and one of the most significant chronic immune-mediated diseases in clinical medicine. The disease follows a highly variable course, ranging from mild, self-limiting disease in a minority of patients to relentlessly progressive joint destruction producing severe disability in others, with the majority of patients experiencing a chronic, fluctuating course that requires lifelong treatment and careful monitoring.
The past three decades have witnessed a transformation in the management of rheumatoid arthritis that represents one of the most significant advances in the history of rheumatology. The development of biological disease-modifying antirheumatic drugs, beginning with tumor necrosis factor inhibitors in the late 1990s, followed by agents targeting B lymphocytes, T lymphocyte co-stimulation, interleukin-6, and intracellular Janus kinase signaling, has provided therapeutic options capable of achieving clinical remission in a substantial proportion of patients and of halting or dramatically slowing radiographic joint damage progression. Combined with the strategic adoption of a treat-to-target management approach that uses systematic disease activity measurement and protocolized treatment escalation to achieve defined remission or low disease activity goals, these advances have made the ambitious goal of remission achievable for many rheumatoid arthritis patients and have shifted the focus of clinical care from merely controlling symptoms to fundamentally changing the disease trajectory.
Immunological Pathogenesis
The immunological mechanisms underlying rheumatoid arthritis have been progressively elucidated by decades of basic and translational research, revealing an extraordinarily complex interplay of innate and adaptive immune cell populations, autoantibodies, inflammatory cytokines, and joint tissue responses that collectively drive the synovial inflammation and joint destruction characterizing the disease. The process begins years before the clinical onset of joint symptoms with the development of anti-citrullinated protein antibodies and rheumatoid factor, autoantibodies detectable in the blood of the majority of rheumatoid arthritis patients that can be present for five to ten years before clinical arthritis manifests. This preclinical autoimmunity phase, during which immune tolerance to citrullinated self-proteins is lost through mechanisms involving genetic risk variants, environmental exposures, and altered mucosal immune responses, represents a potential window for preventive intervention that is the focus of intensive current research.
The transition from preclinical autoimmunity to clinical synovitis reflects the establishment of an inflammatory process within the joint synovium that is driven by the infiltration of autoreactive T lymphocytes, activated B lymphocytes and plasma cells producing rheumatoid factor and anti-citrullinated protein antibodies, and macrophages that produce the dominant pro-inflammatory cytokines of rheumatoid arthritis including tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6. These cytokines act on synoviocytes, chondrocytes, and osteoclasts to drive the proliferation of the synovial membrane into a destructive pannus tissue that invades and erodes the underlying cartilage and bone, producing the erosive joint damage that is the structural hallmark of uncontrolled rheumatoid arthritis and the primary target of disease-modifying treatment.
The interleukin-6 pathway deserves specific attention given its central role in both the articular and systemic manifestations of rheumatoid arthritis and its therapeutic targeting by the monoclonal antibodies tocilizumab and sarilumab. Interleukin-6 drives the acute phase response that produces the elevated C-reactive protein, erythrocyte sedimentation rate, and plasma fibrinogen that characterize active rheumatoid arthritis and contribute to the thrombotic cardiovascular risk of the disease. It promotes the differentiation of osteoclast precursors into mature bone-resorbing osteoclasts, directly driving the periarticular bone erosion and systemic osteoporosis associated with rheumatoid arthritis. It stimulates hepatic production of hepcidin, suppressing intestinal iron absorption and causing the anemia of chronic inflammation that contributes to fatigue. And it acts centrally to drive the constitutional symptoms of fever, fatigue, and malaise that impose significant additional burden on rheumatoid arthritis patients beyond their joint symptoms.
Clinical Features and Diagnosis
The diagnosis of rheumatoid arthritis is based on the integration of clinical features, laboratory findings, and imaging results within the framework of the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria, which provide a systematic scoring approach to the diagnosis of early rheumatoid arthritis that has substantially improved the sensitivity of diagnosis compared to older criteria and has enabled the earlier initiation of disease-modifying treatment that is associated with better long-term outcomes.
The characteristic joint involvement in rheumatoid arthritis follows a symmetric distribution, typically affecting the small joints of the hands, particularly the metacarpophalangeal and proximal interphalangeal joints, the wrists, and the metatarsophalangeal joints of the feet, with larger joints including knees, shoulders, elbows, and ankles frequently involved as the disease progresses. The distal interphalangeal joints of the fingers, which are characteristically affected in osteoarthritis and psoriatic arthritis, are typically spared in rheumatoid arthritis, providing an important clinical differential feature. Joint inflammation in rheumatoid arthritis produces swelling, warmth, tenderness, and synovial thickening that are detectable on clinical examination, alongside the morning stiffness lasting more than one hour that reflects the nighttime accumulation of inflammatory mediators in the joint and is a cardinal symptom of inflammatory joint disease.
The systemic nature of rheumatoid arthritis extends beyond the joints to produce extra-articular manifestations that are present in a significant proportion of patients and contribute to the overall disease burden. Rheumatoid nodules, firm subcutaneous deposits of inflammatory granulomatous tissue that occur most commonly over pressure points including the olecranon, are the most recognizable extra-articular manifestation. Interstitial lung disease, particularly usual interstitial pneumonia and non-specific interstitial pneumonia patterns, represents the most clinically serious extra-articular complication and a significant cause of morbidity and mortality in rheumatoid arthritis patients. Cardiovascular disease risk is substantially elevated in rheumatoid arthritis, driven by chronic systemic inflammation, dyslipidemia secondary to inflammatory cytokine effects on lipid metabolism, and the adverse cardiovascular effects of some traditional rheumatoid arthritis treatments.
Disease-Modifying Treatment Strategies
The treatment of rheumatoid arthritis has been revolutionized by the development and widespread adoption of a treat-to-target strategy in which the goal of management is the achievement of clinical remission or at minimum low disease activity, defined by validated composite disease activity measures, rather than the symptom control that was the primary objective of older management approaches. This strategy requires systematic disease activity assessment using validated measures including the Disease Activity Score in 28 joints, the Clinical Disease Activity Index, or the Simplified Disease Activity Index at regular intervals, typically every one to three months during active disease, and protocolized escalation of treatment when the target state is not achieved.
Methotrexate remains the anchor disease-modifying antirheumatic drug for rheumatoid arthritis, providing the reference standard of efficacy against which all subsequent agents have been evaluated and producing meaningful clinical improvement with acceptable tolerability in the majority of patients. Administered weekly by oral or subcutaneous route at doses of ten to twenty-five milligrams, methotrexate inhibits dihydrofolate reductase and other folate-dependent enzymatic pathways in rapidly dividing immune cells, reducing T lymphocyte and macrophage activation and pro-inflammatory cytokine production. Supplemental folic acid, administered daily, substantially reduces the incidence of methotrexate-related adverse effects including nausea, oral ulceration, and transaminase elevation without reducing efficacy.
When methotrexate at optimal doses fails to achieve the treatment target, the addition of biological or targeted synthetic disease-modifying antirheumatic drugs provides a range of mechanistically distinct escalation options. Tumor necrosis factor inhibitors, available as subcutaneous or intravenous preparations, were the first biological agents approved for rheumatoid arthritis and remain the most widely used biological class, providing rapid and durable reductions in disease activity and radiographic progression in the majority of methotrexate-inadequate responders. For patients who fail tumor necrosis factor inhibitors, a growing portfolio of agents targeting alternative pathways including B lymphocyte depletion with rituximab, T lymphocyte co-stimulation blockade with abatacept, interleukin-6 receptor inhibition with tocilizumab or sarilumab, and Janus kinase inhibition with tofacitinib, baricitinib, or upadacitinib provides sequential treatment options capable of achieving remission in patients who have failed multiple previous lines of therapy.